GlassScriptPhysician profile
John Burgers
NPI 1982622353
$826.41
in general payments reported to CMS, 2019-2025
25 companies · $21.06 in 2025
The $21.06 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $57.60 · 2021: $194 · 2022: $225 · 2023: $68.49 · 2024: $95.06 · 2025: $21.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $132.01 | 2019-2024 | |
| Astellas Pharma US INC | $67.92 | 2019-2021 | |
| Myovant Sciences INC. | $66.53 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $60.73 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $57.77 | 2019-2023 | Aveed, Edex, Xiaflex |
| Genzyme Corporation | $56.93 | 2022 | |
| Dendreon Pharmaceuticals LLC | $46.94 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.17 | 2019-2022 | |
| Teleflex LLC | $29.77 | 2024 | Urolift |
| Janssen Biotech, INC. | $24.85 | 2019 | |
| Progenics Pharmaceuticals, INC. | $24.03 | 2022 | |
| Boston Scientific Corporation | $22.14 | 2021 | |
| Laborie Medical Technologies Corp. | $21.52 | 2024 | Endosheath Technology |
| Accord Healthcare, INC. | $21.06 | 2025 | |
| Blue Earth Diagnostics | $20.56 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $17.86 | 2022 | |
| Amgen INC. | $17.06 | 2019 | |
| Clarus Therapeutics INC. | $15.97 | 2021 | |
| Smith+Nephew, INC. | $15.94 | 2024 | Grafix Pl |
| Olympus America INC. | $14.56 | 2024 | Itind System |
| Abbvie INC. | $14.51 | 2020 | |
| Urogen Pharma, INC. | $13.52 | 2022 | |
| Sumitomo Pharma America, INC. | $13.44 | 2023 | Orgovyx |
| Cook Medical LLC | $12.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$657.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Burgers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.